London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Correct De Bull - its was founded and started in Australia.
Doseme was acquired by Tabula Rasa Health Care for £20 Million Dollars
Tabula Rasa then got rid of the assets as it wasn't a core one and wasn't generating any cash - they eventually sold this for £1.5 Million making a significant Multi million lost
Trench, did they not start off in Oz and have a office there to?
DoseMeRx is a game-changing solution that enables customers to accelerate their precision dosing strategies with superior analytics and reporting. The guideposts of DoseMe’s ongoing investment are to improve overall clinical expertise and valuable clinical decision support to assist customers in offering the highest quality patient care.
This surge in clientele was boosted by strategic partnerships worldwide, underscoring DoseMe’s commitment to global expansion and continuous innovation to deliver advanced precision dosing.
Excellent news Trench
DosemeRx have posted this which suggests they have strong growth ambitions and would be an excellent partner if PYC are able to strike a commercial deal with them
https://doseme-rx.com/news-media/article/doseme-expands-global-footprint-in-australia
On a recent IMC presentation JM mentioned that 'at the point when we mutually decide that we want to move to a commercial phase that will be quite quick because Doseme clients use the tool on a Cloud-based system and it doesn't require a complicated and lengthy roll-out'
I'm a LTH Laura. Bought more last week...
GLA
I was a bit unsure when the company announced that it was initiating a company newsletter
However, I have been impressed by how much relevant news has been contained in the first few issues. It is a credit to the determined effort PYC are making to improve the profile of the company. Lets hope this continues in the near term with details regarding the Head of Modelling appointment, maybe an update on the G-CSF project, some important news on the Biostatistics initiative, contract announcements etc. Exciting times for those with a genuine interest
This person is very odd
Click on their posting summaries, every day if every week they post the same drivel on 100s of shares
Prostate cancer and "cell dormancy "
Dr Green said the funding, of £2.34m from The Wellcome Trust and £500,000 from Yorkshire Cancer Research, would "bring together international experts to gain a deeper understanding of cancer cell dormancy in myeloma".
"By better understanding the cells, this research can either make Karonudib more effective, or may help generate completely new treatments," she said.
She said the additional money from Yorkshire Cancer Research would also fund research into cell dormancy in cancers that spread to bone, like breast and prostate cancer.
Brilliant news..thanks Ralph
Pyc announced contract with Sheffield Uni etc in February, BBC announced following.
More than £2.5m will be ploughed into new research into blood cancer in Sheffield, it has been announced.
The University of Sheffield was given the funding to look into dormant cancer cells and develop new treatments for myeloma, a type of blood cancer.
https://x.com/physiomics/status/1780186840005259327?s=61&t=0G9XeE3tHfuoBf1VEsPycQ
Still maximum buy of 200,000 shares (£2500)
Been like this for 5 + days now ?
Clear to see that the "traders" like Hopist didn't last long
77k and 96k sells today were bought on Friday
Glad they're out to be honest...
Debull
There has been low interest cross WHOLE of AIM last 18mths not just PYC
Also all PYC can do is keep on increasing client base and revenues..which they are doing..Peter looks like the person to drive this even further
You would have thought so Laura?
However, the lowly SP and near lack of interest in people buying these shares, along with only a trickle of deals, shows that either there is fierce competition within this particular market, or what PYC are offering is not (yet) needed by drug development companies or these companies are getting the data they need from other sources or in house?
PYC have said they are in the "sweet spot", yet this sweet spot has not amounted to much yet? Maybe the FDA's #ProjectOptimus can be the saviour?
Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million1.
Thankyou debull
I believe it was completed sometime ago,
https://www.physiomics.co.uk/wp-content/uploads/2019/04/2017-1-11-Company-Update-2.pdf
We are talking 2015-16 timelines here?
The candidate was CCT245737, which was renamed PNT737, then licensed out to Sierra by which time it was SRA737 https://www.edisongroup.com/research/sierra-oncology-returns-rights-to-sra737/31442/ Sierra bought out by GSK and then SRA737 rights were returned to SAR after GSK's purchase of Sierra. Or something along those lines!
What it does show is that PYC have been on this "Personal medicine" train for nearly a decade.
the original link was when i was looking at an article on immunology on the sar discussion group.
as an aside, i think trench123 said we still have an agreement with sar (or had that now completed?)
https://www.fiercebiotech.com/medtech/roche-picks-prenosis-newly-cleared-sepsis-ai-tool-distribution?itm_source=p****ly-api
This may not be relevant at all but thought it was interesting regarding what Ant said about the potential value of PYC/Doseme A.I tool
The ImmunoScore AI works with electronic health records to digest 22 pieces of clinical information and assigns a patient a risk level linked to the possibility of developing sepsis complications. (JazzIRT/GettyImage)
Following last week’s de novo clearance for the artificial intelligence program, Roche has stepped up to distribute Prenosis’ sepsis risk prediction tool through its diagnostic platforms.
The startup’s ImmunoScore software will be made available to hospital labs and emergency departments through Roche’s navify Algorithm Suite. The financial details of the agreement were not disclosed.
Yeah spread is 12% atm. Went down to 9% for a while. Not much liquidity then....1 sell of £232.20, took the bid down from 1.61p down to 1.2p. Bodes well if people start buying tho'
Can’t see any ramping tbh but valid point. Spread awful has been for a while was 30% a few days ago
1.40 close above and its game on
https://invst.ly/14digm
You got to love ramping traders, all part of the fun....
Just an 18% increase in the market cap to cover the spread then you look to make a profit...
LMOL
Nicely understated eh?!
JUST HURRY UP AND BUY